

Press Release

22 April 2022 18:00:00 CEST

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022

Corrections have been made to “Shareholder who wish to participate at the general meeting must” changing from the 17th May to 16th May and to “Nominee registered shares” changing from the 17th May to 18th May and elaboration of the procedures.

The correct version is attached to this press release.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

Certified Adviser

Redeye AB
Phone: +46 8 121 576 90
Mail: certifiedadviser@redeye.se

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com.

Attachments

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022
20220421 2cureX Notice Annual General Meeting UK CORRECTED